Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility
European Urology Focus, ISSN: 2405-4569, Vol: 7, Issue: 2, Page: 231-233
2021
- 3Citations
- 5Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations3
- Citation Indexes3
- Captures5
- Readers5
Article Description
Prostate-specific membrane antigen–based theranostics are likely to become important tools for the management of prostate cancer. However, data proving their clinical utility are urgently required before implementation of their use outside clinical trials, and their off-trial use needs to be better regulated.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2405456921000109; http://dx.doi.org/10.1016/j.euf.2021.01.009; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85099799905&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33495132; https://linkinghub.elsevier.com/retrieve/pii/S2405456921000109; https://dx.doi.org/10.1016/j.euf.2021.01.009
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know